Schwartz Z et al. |
Osteoprotegerin (OPG) production by cells in the osteoblast lineage is regulated by pulsed electromagnetic fields in cultures grown on calcium phosphate substrates. |
2009 |
Ann Biomed Eng |
pmid:19139991
|
Liu J et al. |
Pressure-loaded MSCs during early osteodifferentiation promote osteoclastogenesis by increase of RANKL/OPG ratio. |
2009 |
Ann Biomed Eng |
pmid:19148752
|
Schlieper G et al. |
Analysis of calcifications in patients with coral reef aorta. |
2010 |
Ann Vasc Surg |
pmid:20144533
|
Buckley KA and Fraser WD |
Receptor activator for nuclear factor kappaB ligand and osteoprotegerin: regulators of bone physiology and immune responses/potential therapeutic agents and biochemical markers. |
2002 |
Ann. Clin. Biochem. |
pmid:12564836
|
Hofbauer LC |
Pathophysiology of RANK ligand (RANKL) and osteoprotegerin (OPG). |
2006 |
Ann. Endocrinol. (Paris) |
pmid:16639364
|
Quemerais-Durieu MA et al. |
[Therapeutic innovation in osteoporosis (antisclerostin antibody and denosumab)]. |
2011 |
Ann. Endocrinol. (Paris) |
pmid:22008272
|
Perifanis V et al. |
Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia. |
2007 |
Ann. Hematol. |
pmid:17013645
|
Christoforidis A et al. |
Increased osteoclastic activity as shown by increased sRANK-L/OPG ratio in boys with hemophilia. |
2010 |
Ann. Hematol. |
pmid:20084381
|
Korostishevsky M et al. |
Anthropometric and bone-related biochemical factors are associated with different haplotypes of ANKH locus. |
2008 Sep-Oct |
Ann. Hum. Biol. |
pmid:18821330
|
Kwan JS et al. |
Heritability of serum osteoprotegerin. |
2011 |
Ann. Hum. Genet. |
pmid:21762114
|
Vistoropsky Y et al. |
Osteoprotegerin plasma levels are strongly associated with polymorphisms in human homologue of the mouse progressive ankylosis (ANKH) gene. |
2007 |
Ann. Hum. Genet. |
pmid:17147692
|
Priyadarshi S et al. |
Genetic association and altered gene expression of osteoprotegerin in otosclerosis patients. |
2015 |
Ann. Hum. Genet. |
pmid:25998045
|
Dovio A et al. |
[Pathophysiological significance and clinical utility of circulating osteoprotegerin]. |
2004 Jan-Mar |
Ann. Ital. Med. Int. |
pmid:15176704
|
Schinke T et al. |
Molecular determinants of arterial calcification. |
1998 |
Ann. Med. |
pmid:9920355
|
MacNee W |
Systemic inflammatory biomarkers and co-morbidities of chronic obstructive pulmonary disease. |
2013 |
Ann. Med. |
pmid:23110517
|
Montagnana M et al. |
The role of osteoprotegerin in cardiovascular disease. |
2013 |
Ann. Med. |
pmid:23110639
|
Weitzmann MN and Pacifici R |
T cells: unexpected players in the bone loss induced by estrogen deficiency and in basal bone homeostasis. |
2007 |
Ann. N. Y. Acad. Sci. |
pmid:18083938
|
Wimalawansa SJ |
Rationale for using nitric oxide donor therapy for prevention of bone loss and treatment of osteoporosis in humans. |
2007 |
Ann. N. Y. Acad. Sci. |
pmid:18056048
|
Lin-Su K and New MI |
Effects of adrenal steroids on the bone metabolism of children with congenital adrenal hyperplasia. |
2007 |
Ann. N. Y. Acad. Sci. |
pmid:18056052
|
Leibbrandt A and Penninger JM |
RANK/RANKL: regulators of immune responses and bone physiology. |
2008 |
Ann. N. Y. Acad. Sci. |
pmid:19076348
|
Glass DA and Karsenty G |
Canonical Wnt signaling in osteoblasts is required for osteoclast differentiation. |
2006 |
Ann. N. Y. Acad. Sci. |
pmid:16831912
|
Whyte MP |
Paget's disease of bone and genetic disorders of RANKL/OPG/RANK/NF-kappaB signaling. |
2006 |
Ann. N. Y. Acad. Sci. |
pmid:16831914
|
Zallone A |
Direct and indirect estrogen actions on osteoblasts and osteoclasts. |
2006 |
Ann. N. Y. Acad. Sci. |
pmid:16831916
|
Liu XH et al. |
Interactive effect of interleukin-6 and prostaglandin E2 on osteoclastogenesis via the OPG/RANKL/RANK system. |
2006 |
Ann. N. Y. Acad. Sci. |
pmid:16831922
|
Matsumoto T and Abe M |
Bone destruction in multiple myeloma. |
2006 |
Ann. N. Y. Acad. Sci. |
pmid:16831932
|
Brunetti G et al. |
The role of OPG/TRAIL complex in multiple myeloma: the OPG/TRAIL complex in an in vitro osteoclastogenesis model derived from human multiple myeloma-bone disease. |
2006 |
Ann. N. Y. Acad. Sci. |
pmid:16831934
|
Boumans MJ et al. |
Rituximab abrogates joint destruction in rheumatoid arthritis by inhibiting osteoclastogenesis. |
2012 |
Ann. Rheum. Dis. |
pmid:22072013
|
Sagar DR et al. |
Osteoprotegerin reduces the development of pain behaviour and joint pathology in a model of osteoarthritis. |
2014 |
Ann. Rheum. Dis. |
pmid:23723320
|
Castellino G et al. |
Is there any role for tumour necrosis factor related apoptosis inducing ligand-osteoprotegerin (TRAIL-OPG) interaction in rheumatoid arthritis? |
2008 |
Ann. Rheum. Dis. |
pmid:18621972
|
Itonaga I et al. |
Effect of osteoprotegerin and osteoprotegerin ligand on osteoclast formation by arthroplasty membrane derived macrophages. |
2000 |
Ann. Rheum. Dis. |
pmid:10627423
|
Skoumal M et al. |
Serum osteoprotegerin but not receptor activator of NF-kappaB ligand correlates with Larsen score in rheumatoid arthritis. |
2004 |
Ann. Rheum. Dis. |
pmid:14722219
|
Gengenbacher M et al. |
Infliximab inhibits bone resorption by circulating osteoclast precursor cells in patients with rheumatoid arthritis and ankylosing spondylitis. |
2008 |
Ann. Rheum. Dis. |
pmid:17720725
|
Ruocco MG and Karin M |
IKK{beta} as a target for treatment of inflammation induced bone loss. |
2005 |
Ann. Rheum. Dis. |
pmid:16239395
|
Smith MD et al. |
Microarchitecture and protective mechanisms in synovial tissue from clinically and arthroscopically normal knee joints. |
2003 |
Ann. Rheum. Dis. |
pmid:12634226
|
Crotti TN et al. |
Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. |
2002 |
Ann. Rheum. Dis. |
pmid:12429533
|
Dai SM et al. |
Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 beta and tumour necrosis factor alpha. |
2004 |
Ann. Rheum. Dis. |
pmid:15479886
|
Wagner EF and Matsuo K |
Signalling in osteoclasts and the role of Fos/AP1 proteins. |
2003 |
Ann. Rheum. Dis. |
pmid:14532157
|
van Tuyl LH et al. |
Baseline RANKL:OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritis. |
2010 |
Ann. Rheum. Dis. |
pmid:20525836
|
Pathan E et al. |
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis. |
2013 |
Ann. Rheum. Dis. |
pmid:22984171
|
Feige U |
Osteoprotegerin. |
2001 |
Ann. Rheum. Dis. |
pmid:11890662
|
O' Gradaigh D et al. |
Joint erosion in rheumatoid arthritis: interactions between tumour necrosis factor alpha, interleukin 1, and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclasts. |
2004 |
Ann. Rheum. Dis. |
pmid:15020327
|
Jones DH et al. |
Role of RANKL and RANK in bone loss and arthritis. |
2002 |
Ann. Rheum. Dis. |
pmid:12379618
|
González-Alvaro I et al. |
Baseline serum RANKL levels may serve to predict remission in rheumatoid arthritis patients treated with TNF antagonists. |
2007 |
Ann. Rheum. Dis. |
pmid:17666448
|
Gravallese EM |
Bone destruction in arthritis. |
2002 |
Ann. Rheum. Dis. |
pmid:12379632
|
Vis M et al. |
Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. |
2006 |
Ann. Rheum. Dis. |
pmid:16606653
|
Bao BY et al. |
Clinical significance of tumor necrosis factor receptor superfamily member 11b polymorphism in prostate cancer. |
2010 |
Ann. Surg. Oncol. |
pmid:20204532
|
Kress DC |
Invited commentary. |
2013 |
Ann. Thorac. Surg. |
pmid:23992687
|
Cao H et al. |
Preoperative serum soluble receptor activator of nuclear factor-κB ligand and osteoprotegerin predict postoperative atrial fibrillation in patients undergoing cardiac valve surgery. |
2013 |
Ann. Thorac. Surg. |
pmid:23870696
|
Walsh MC et al. |
Osteoimmunology: interplay between the immune system and bone metabolism. |
2006 |
Annu. Rev. Immunol. |
pmid:16551243
|
Theill LE et al. |
RANK-L and RANK: T cells, bone loss, and mammalian evolution. |
2002 |
Annu. Rev. Immunol. |
pmid:11861618
|
Pettersen I et al. |
Osteoprotegerin is expressed in colon carcinoma cells. |
2005 Nov-Dec |
Anticancer Res. |
pmid:16309167
|
Katopodis H et al. |
MG-63 osteoblast-like cells enhance the osteoprotegerin expression of PC-3 prostate cancer cells. |
2009 |
Anticancer Res. |
pmid:19846944
|
Zojer N et al. |
Bisphosphonate treatment does not affect serum levels of osteoprotegerin and RANKL in hypercalcemic cancer patients. |
2005 Sep-Oct |
Anticancer Res. |
pmid:16101188
|
Owen S et al. |
Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer. |
2013 |
Anticancer Res. |
pmid:23267146
|
Brown TT et al. |
Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens. |
2011 |
Antivir. Ther. (Lond.) |
pmid:22024522
|
Belibasakis GN et al. |
Cytolethal distending toxin upregulates RANKL expression in Jurkat T-cells. |
2008 |
APMIS |
pmid:18754324
|
Krajewski AC et al. |
Influence of lipopolysaccharide and interleukin-6 on RANKL and OPG expression and release in human periodontal ligament cells. |
2009 |
APMIS |
pmid:19775343
|
Esteghamati A et al. |
Association of osteoprotegerin with peripheral artery disease in patients with type 2 diabetes. |
2015 Aug-Sep |
Arch Cardiovasc Dis |
pmid:26184866
|
Marques EA et al. |
Response of bone mineral density, inflammatory cytokines, and biochemical bone markers to a 32-week combined loading exercise programme in older men and women. |
2013 Sep-Oct |
Arch Gerontol Geriatr |
pmid:23623588
|
Esteghamati A et al. |
Serum osteoprotegerin in relation to metabolic status, severity, and estimated risk of subsequent coronary heart disease. |
2014 |
Arch Iran Med |
pmid:25204474
|
Lee JS et al. |
Changes in serum levels of receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, IL-6 and TNF-alpha in patients with a concomitant head injury and fracture. |
2009 |
Arch Orthop Trauma Surg |
pmid:18427820
|
Del Fattore A et al. |
Osteoclast receptors and signaling. |
2008 |
Arch. Biochem. Biophys. |
pmid:18237538
|
Merewether LA et al. |
Development of disulfide peptide mapping and determination of disulfide structure of recombinant human osteoprotegerin chimera produced in Escherichia coli. |
2000 |
Arch. Biochem. Biophys. |
pmid:10683254
|
Boyce BF and Xing L |
Functions of RANKL/RANK/OPG in bone modeling and remodeling. |
2008 |
Arch. Biochem. Biophys. |
pmid:18395508
|
Helfrich MH and Hocking LJ |
Genetics and aetiology of Pagetic disorders of bone. |
2008 |
Arch. Biochem. Biophys. |
pmid:18359282
|
Kuroyanagi G et al. |
Resveratrol suppresses prostaglandin F(2α)-induced osteoprotegerin synthesis in osteoblasts: inhibition of the MAP kinase signaling. |
2014 |
Arch. Biochem. Biophys. |
pmid:24333336
|
Kim H et al. |
Association between endometriosis and polymorphisms in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), TRAIL receptor and osteoprotegerin genes and their serum levels. |
2012 |
Arch. Gynecol. Obstet. |
pmid:22392486
|
Eren MA et al. |
Association of parity with osteoprotegerin levels and atherosclerosis. |
2013 |
Arch. Gynecol. Obstet. |
pmid:23287888
|
Kraj M et al. |
Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients. |
2005 Sep-Oct |
Arch. Immunol. Ther. Exp. (Warsz.) |
pmid:16314829
|
Åšwierkot J et al. |
Assessment of the Effect of Methotrexate Therapy on Bone Metabolism in Patients with Rheumatoid Arthritis. |
2015 |
Arch. Immunol. Ther. Exp. (Warsz.) |
pmid:25837853
|
Zdzisińska B et al. |
Dysregulation of the receptor activator of NF-kappaB ligand and osteoprotegerin production influence the apoptosis of multiple myeloma patients' bone marrow stromal cells co-cultured with myeloma cells. |
2010 |
Arch. Immunol. Ther. Exp. (Warsz.) |
pmid:20157786
|
Ugur-Altun B and Altun A |
Circulating leptin and osteoprotegerin levels affect insulin resistance in healthy premenopausal obese women. |
2007 |
Arch. Med. Res. |
pmid:17923273
|
Kerr NM et al. |
Ocular manifestations of juvenile Paget disease. |
2010 |
Arch. Ophthalmol. |
pmid:20547946
|
Tripuwabhrut P et al. |
Effect of compressive force on human osteoblast-like cells and bone remodelling: an in vitro study. |
2013 |
Arch. Oral Biol. |
pmid:23583016
|
Wada Y et al. |
Enamel matrix derivative neutralized the effect of lipopolysaccharide on osteoprotegerin and receptor activator of nuclear factor kappa B ligand expression of osteoblasts. |
2009 |
Arch. Oral Biol. |
pmid:19201394
|
Zhang D et al. |
The expression of osteoprotegerin and the receptor activator of nuclear factor kappa B ligand in human periodontal ligament cells cultured with and without 1alpha,25-dihydroxyvitamin D3. |
2004 |
Arch. Oral Biol. |
pmid:14693199
|
Nonaka CF et al. |
Immunohistochemical analysis of bone resorption regulators (RANKL and OPG), angiogenic index, and myofibroblasts in syndrome and non-syndrome odontogenic keratocysts. |
2012 |
Arch. Oral Biol. |
pmid:21871606
|
Dalla-Bona DA et al. |
Cementoblast response to low- and high-intensity ultrasound. |
2008 |
Arch. Oral Biol. |
pmid:18163974
|
Wen Y et al. |
Application of eGFP to label human periodontal ligament stem cells in periodontal tissue engineering. |
2012 |
Arch. Oral Biol. |
pmid:22410147
|
Mayahara K et al. |
Osteoblasts stimulate osteoclastogenesis via RANKL expression more strongly than periodontal ligament cells do in response to PGE(2). |
2012 |
Arch. Oral Biol. |
pmid:22884709
|
Liao C and Hua Y |
Effect of hydrogen sulphide on the expression of osteoprotegerin and receptor activator of NF-κB ligand in human periodontal ligament cells induced by tension-force stimulation. |
2013 |
Arch. Oral Biol. |
pmid:24200305
|
Luvizuto ER et al. |
Histomorphometric analysis and immunolocalization of RANKL and OPG during the alveolar healing process in female ovariectomized rats treated with oestrogen or raloxifene. |
2010 |
Arch. Oral Biol. |
pmid:19948337
|
Wattanaroonwong N et al. |
Oestrogen inhibits osteoclast formation induced by periodontal ligament fibroblasts. |
2011 |
Arch. Oral Biol. |
pmid:21035111
|
Jacobs C et al. |
Osteogenic differentiation of periodontal fibroblasts is dependent on the strength of mechanical strain. |
2013 |
Arch. Oral Biol. |
pmid:23422327
|
Bastos MF et al. |
Effects of Cachaça, a typical Brazilian alcoholic beverage, on alveolar bone loss and density: a study in peripubertal rats. |
2014 |
Arch. Oral Biol. |
pmid:24183604
|
Nishigaki M et al. |
β-cryptoxanthin regulates bone resorption related-cytokine production in human periodontal ligament cells. |
2013 |
Arch. Oral Biol. |
pmid:23452546
|
de Moraes M et al. |
Comparative immunohistochemical expression of RANK, RANKL and OPG in radicular and dentigerous cysts. |
2011 |
Arch. Oral Biol. |
pmid:21683340
|
Sheng ZF et al. |
OPG knockout mouse teeth display reduced alveolar bone mass and hypermineralization in enamel and dentin. |
2010 |
Arch. Oral Biol. |
pmid:20233613
|
Tazoe M et al. |
Involvement of p38MAP kinase in bone morphogenetic protein-4-induced osteoprotegerin in mouse bone-marrow-derived stromal cells. |
2003 |
Arch. Oral Biol. |
pmid:12828991
|
Luvizuto ER et al. |
Raloxifene therapy inhibits osteoclastogenesis during the alveolar healing process in rats. |
2011 |
Arch. Oral Biol. |
pmid:21536255
|
de Souza JA et al. |
Expression of suppressor of cytokine signaling 1 and 3 in ligature-induced periodontitis in rats. |
2011 |
Arch. Oral Biol. |
pmid:21511249
|
Kim SJ et al. |
Compressive stress induced the up-regulation of M-CSF, RANKL, TNF-α expression and the down-regulation of OPG expression in PDL cells via the integrin-FAK pathway. |
2013 |
Arch. Oral Biol. |
pmid:23219295
|
Tang X and Meng H |
Osteogenic induction and 1,25-dihydroxyvitamin D3 oppositely regulate the proliferation and expression of RANKL and the vitamin D receptor of human periodontal ligament cells. |
2009 |
Arch. Oral Biol. |
pmid:19464673
|
Katono T et al. |
Sodium butyrate stimulates mineralized nodule formation and osteoprotegerin expression by human osteoblasts. |
2008 |
Arch. Oral Biol. |
pmid:18406397
|
Inubushi T et al. |
Lactoferrin inhibits infection-related osteoclastogenesis without interrupting compressive force-related osteoclastogenesis. |
2014 |
Arch. Oral Biol. |
pmid:24370195
|
Wise GE et al. |
Inhibition of osteoclastogenesis by the secretion of osteoprotegerin in vitro by rat dental follicle cells and its implications for tooth eruption. |
2002 |
Arch. Oral Biol. |
pmid:11839361
|
Kadkhodazadeh M et al. |
Analysis of RANKL gene polymorphism (rs9533156 and rs2277438) in Iranian patients with chronic periodontitis and periimplantitis. |
2013 |
Arch. Oral Biol. |
pmid:23177932
|
Lee MH et al. |
The effect of surface microgrooves and anodic oxidation on the surface characteristics of titanium and the osteogenic activity of human periodontal ligament cells. |
2013 |
Arch. Oral Biol. |
pmid:22717323
|
Heinrich J et al. |
CSF-1, RANKL and OPG regulate osteoclastogenesis during murine tooth eruption. |
2005 |
Arch. Oral Biol. |
pmid:16137499
|
Ramirez-Yanez GO and Symons AL |
Prostaglandin E2 affects osteoblast biology in a dose-dependent manner: an in vitro study. |
2012 |
Arch. Oral Biol. |
pmid:22480456
|